Catalog No.
Product Name
Application
Product Information
Citations
-
Na+/H+ exchanger inhibitor
5-(N,N-Hexamethylene)-amiloride (Hexamethylene amiloride) derives from an amiloride and is a potent Na+/H+ exchanger inhibitor, which decreases the intracellular pH (pHi) and induces apoptosis in leukemic cells. -
NaV 1.7 inhibitor
NaV1.7 inhibitor-1 is an efficacious voltage-gated sodium channel (NaV) 1.7 inhibitor with an IC50 of 0.6 nM for hNaV1.7, exhibits 80-fold selectivity versus hNaV1.5. - Eslicarbazepine is an oral anticonvulsant indicated for the adjunctive treatment of partial seizures.
-
SLC34A1 inhibitor
PF-06869206 is an orally bioavailable selective inhibitor of the sodium-phosphate cotransporter NaPi2a (SLC34A1) with an IC50 of 380 nM. -
NaV1.8 blocker
PF 04531083 is a selective NaV1.8 blocker, and used for the research of neuropathic/inflammatory pain. -
Nav1.7 inhibitor
PF-05241328 is a potent and selective inhibitor of human Nav1.7 voltage-dependent sodium channels (Nav1.7), with an IC50 of 31 nM. -
Na+ blocker
Ralfinamide (FCE-26742A) is an orally available Na+ blocker derived from α-aminoamide, with function of suppressing pain. -
sodium channel blocker
Sodium Channel inhibitor 2 is a sodium channel blocker extracted from patent WO 2004011439 A2, compound 3c. -
Nav1.8 channel blocker
PF-01247324 is a selective and orally bioavailable Nav1.8 channel blocker with an IC50 of 196 nM for recombinant human Nav1.8 channel. -
HIF-1α inhibitor
Minocycline hydrochloride is a broad-spectrum tetracycline antibiotic, acting by binding to the bacterial 30S ribosomal subunit and inhibiting protein synthesis.- Viktoria Lazar, .et al. , Nature, 2022, 610: 540-546 PMID: 36198788
-
Nav1.7 sodium channel inhibitor
Raxatrigine hydrochloride (GSK-1014802 hydrochloride) is a novel small molecule state-dependent sodium channel blocker; Nav1.7 sodium channel inhibitor. -
Na+ channel blocker
Ralfinamide mesylate (FCE-26742A mesylate) is an orally available Na+ channel blocker derived from α-aminoamide, with function of suppressing pain. -
inhibitor of Kv2.1 and Kv2.2
RY785 (Kv2-IN-A1) is an inhibitor of Kv2.1 and Kv2.2. -
sodium channel blocker
Levobupivacaine hydrochloride is a sodium channel blocker. - Eleclazine, also known as GS-6615, is a selective late sodium current inhibitor. Eleclazine is potentially useful for treatment of coronary vasodilators, antiarrhythmics and vasodilators.
-
blocker of fast Na+-dependent action potentials and voltage-dependent
Lidocaine N-ethyl bromide is a non-membrane-permeable blocker of fast Na+-dependent action potentials and voltage-dependent, non-inactivating Na+ conductance. -
DNA Dye
DAPI (4',6-Diamidino-2-phenylindole) is a fluorescent DNA dye that selectively binds to the AT base pairs in the minor groove of double-stranded DNA, enhancing fluorescence intensity approximately 20-fold upon binding. This property makes DAPI suitable for applications in fluorescence microscopy, allowing for quantification of DNA based on fluorescence intensity. Additionally, DAPI's ability to penetrate intact cell membranes enables its use in staining both live and fixed cells. DAPI also acts as an inhibitor of acid-sensing ion channel 3 (ASIC3), potentially contributing to research in chronic pain treatment (Ex/Em = 356/451 nm). -
Estrogen Receptor Agonist, Voltage-Gated Sodium Channel Blocker, PI3K-AKT/JNK Signaling Modulator,
Propylparaben sodium acts as a weak estrogen receptor agonist and serves as a voltage-gated sodium channel blocker, while also modulating the PI3K-AKT and JNK signaling pathways. It is known to induce oxidative stress, affecting the estrous cycle and hormone levels, as well as ovarian reserve function. Propylparaben sodium can inhibit the growth of antral follicles and influence the accumulation of steroid hormones in follicle culture media. This compound is suitable for research related to ovarian aging and myocardial ischemia-reperfusion injury. -
Sodium Channel Inhibitor
Articaine is a selective inhibitor of voltage-gated sodium channels, including rNav1.4, hNav1.7, and rNav1.8, demonstrating an IC50 of 15.8 μM for open-state Na+ channels. It effectively blocks Na+ influx, leading to local anesthetic effects and interruption of nerve impulse conduction. Additionally, Articaine exhibits anti-inflammatory properties by inhibiting NF-κB activation and the NLRP3 inflammasome pathway. This compound is valuable for research in dental anesthesia and inflammatory-related conditions, such as acute kidney injury. -
Sodium Channel Inhibitor
Lamotrigine-13C3 is a stable isotope-labeled derivative of Lamotrigine, a highly effective sodium channel inhibitor. This compound selectively targets voltage-gated Na+ channels, leading to stabilization of presynaptic neuronal membranes and a subsequent reduction in glutamate release. Lamotrigine-13C3 is suitable for research applications related to epilepsy, focal seizures, and other neurological disorders. -
Antiarrhythmic Agent
HNS-32 is an antiarrhythmic agent that demonstrates vasodilatory effects, providing protective benefits against ischemic and reperfusion arrhythmias in canine hearts. This compound exhibits significant negative chronotropic effects on mammalian ventricular myocardium, highlighting its potential for applications in acute coronary syndrome research. HNS-32 serves as a valuable tool for exploring the mechanisms and treatment options for cardiac arrhythmias. -
Sodium Channel Agonist
Cevadine is a voltage-sensitive sodium channel agonist that exhibits insecticidal activity. This compound acts by enhancing sodium ion influx through channels, leading to disruption of neuromuscular function in target organisms. Cevadine is valuable for research in neurobiology and agricultural sciences, particularly in studying sodium channel dynamics and developing pest control strategies. -
Sodium Channel Inhibitor
Decarbamoylsaxitoxin is a potent sodium channel inhibitor that selectively blocks the influx of sodium ions in excitable tissues, such as nerve and skeletal muscle cells, thus preventing action potential generation. As a hydrolysis product of saxitoxin, Decarbamoylsaxitoxin exhibits similar neurotoxic effects, including the ability to inhibit veratridine- and ouabain-induced neuroblastoma cell swelling and lysis. This reagent is valuable for research involving mechanisms of paralytic shellfish poisoning and sodium channel pharmacology. -
Sodium Channel Blocker
CAY10568 is a sodium channel blocker that modulates neuronal excitability. This compound, a derivative of QX-314, exhibits a smaller and less hydrophobic profile, making it suitable for exploring its effects on inflammation and pain perception. CAY10568 is valuable for research applications aimed at understanding pain mechanisms and developing analgesic therapies. -
Sodium Channel Inhibitor
(-)-Sparteine sulfate pentahydrate is a sodium channel inhibitor that acts as a class 1a antiarrhythmic agent. It has demonstrated notable biological activity in modulating cardiac excitability and can be utilized in research focusing on arrhythmias and pharmacological studies related to ion channel function. This reagent is suitable for investigating the effects of sodium channel blockade in various biological models. -
Nav1.7 Inhibitor
Nav1.7-IN-6 is a selective inhibitor targeting the voltage-gated sodium channel Nav1.7, which is important in pain signaling pathways. This compound demonstrates significant biological activity in modulating neuronal excitability, making it a valuable tool for research on pain mechanisms and potential therapeutic interventions in pain disorders. Its specificity for Nav1.7 enhances its utility in elucidating the role of this channel in nociception and related studies. -
NaV1.7 Antagonist
AMG8379 is a selective sulfonamide antagonist targeting the voltage-gated sodium channel NaV1.7. It demonstrates potent inhibition with IC50 values of 8.5 nM for human NaV1.7 and 18.6 nM for mouse NaV1.7, effectively blocking TTX-sensitive sodium channels in dorsal root ganglia (DRG) neurons with an IC50 of 3.1 nM. This compound is useful for research applications related to pain pathways and sodium channel modulation. -
Sodium Channel Inhibitor
B-GYKI-38233 hydrochloride is a sodium channel inhibitor that exhibits potent antiarrhythmic properties. This compound is utilized in research focused on the modulation of sodium channels, which play a critical role in cardiac excitability and conductivity. Its mechanism of action makes it a valuable tool for the investigation of arrhythmias and related cardiovascular disorders. -
Nav1.8 channel Inhibitor
Nav1.8-IN-10 is a selective inhibitor of the Nav1.8 ion channel. At a concentration of 4 nM, it achieves an impressive blocking rate of 79.4%, demonstrating its potency. This compound is primarily utilized in the research of pain disorders, facilitating investigations into the modulation of pain pathways and potential therapeutic interventions. -
Nav1.8 Inhibitor
Nav1.8-IN-5 is a selective inhibitor of the voltage-gated sodium channel Nav1.8. It demonstrates potent biological activity against Nav1.8-mediated pain and pain-related disorders, making it a valuable tool for research in these areas. Additionally, Nav1.8-IN-5 can facilitate studies related to cardiovascular diseases, including conditions such as atrial fibrillation, by modulating sodium channel activity. -
Sodium Channel Inhibitor
R 59494 is a sodium channel inhibitor that effectively blocks Na+ and Ca2+ uptake triggered by veratridine exposure. This compound exhibits significant anti-ischemic properties, making it valuable for research in cardiovascular and neuroprotective studies. Its ability to modulate ion channel activity positions R 59494 as a useful tool for investigating the mechanisms of ischemia-related cellular damage. -
Nav1.7 Blocker
NAV 26 is a selective blocker of the voltage-gated sodium channel Nav1.7, exhibiting an IC50 of 0.37 μM. This compound is valuable for investigating pain mechanisms and developing novel analgesics. Its specificity for Nav1.7 makes it a crucial tool in researching pain pathways and potential therapeutic interventions. -
NaV1.8 Channel Inhibitor
Analgesic agent-2 is a selective NaV1.8 channel inhibitor, exhibiting a reported IC50 of 50.18 nM in HEK293 cells expressing the human NaV1.8 channel. It demonstrates significant analgesic activity, making it a valuable tool for pain research. This compound is ideal for studies investigating the role of NaV1.8 in nociception and the development of novel analgesic therapies. -
Nav1.8 Inhibitor
Nav1.8-IN-15 is a potent inhibitor of the voltage-gated sodium channel Nav1.8. It demonstrates significant analgesic effects and is relevant for research exploring pathways involved in chronic pain management. This compound can facilitate the study of Nav1.8's role in pain signaling and aid in the development of novel therapeutic strategies for pain relief. -
NaV1.7 Antagonist
AMG8380 is a selective antagonist of the voltage-gated sodium channel NaV1.7, exhibiting IC50 values of 0.907 µM and 0.387 µM in human and mouse tissues, respectively. This compound effectively inhibits Tetrodotoxin (TTX)-sensitive native channels with an IC50 of 2560 nM, making it a valuable tool for research on pain pathways and sodium channel function. Its properties allow for exploration of NaV1.7's role in nociception and related applications in pharmacological studies. -
NaV1.7 Inhibitor
Sodium Channel-IN-7 is a selective inhibitor of the NaV1.7 voltage-gated sodium channel. It interacts with the voltage-sensor domain 4 (VSD4) binding pocket of NaV1.7, demonstrating limited interaction with residue Try1537. This compound is primarily utilized in research focused on pain mechanisms and pain-related disorders. -
Sodium Channel Inhibitor
Cofirasersen is a sodium channel inhibitor that targets the epithelial sodium channel (ENaC). It is specifically developed to downregulate ENaC expression in the lungs, where hyperactivity of ENaC is implicated in cystic fibrosis, a disorder linked to mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. This compound has potential applications in research related to cystic fibrosis and the modulation of sodium transport in pulmonary tissues. -
Nav1.7 Antagonist
Nav1.7-IN-15 is a potent state-dependent antagonist of the sodium channel Nav1.7, exhibiting an IC50 of 0.42 μM for human Nav1.7 PX. This compound is valuable for studying pain mechanisms and is useful in research focusing on neuropathic pain and other conditions associated with Nav1.7 activity. Its ability to selectively inhibit Nav1.7 makes it an important tool for investigating the therapeutic potential of sodium channel modulation. -
NaV1.7 Inhibitor
PF-06456384 is a potent and selective inhibitor of NaV1.7, exhibiting an IC50 of 0.01 nM. This compound is primarily utilized in research involving pain mechanisms, particularly in formalin pain model studies, to elucidate the role of NaV1.7 in nociceptive signaling. Its high selectivity makes it an important reagent for exploring therapeutic strategies targeting chronic pain conditions. -
Sodium Channel Inhibitor
Nav1.8-IN-1 is a selective inhibitor of the Na(v)1.8 sodium channel, demonstrating significant potency in blocking its activity. This compound is particularly relevant for research focused on inflammatory and neuropathic pain pathways, providing valuable insights into pain mechanisms and potential therapeutic strategies. Its ability to modulate sodium channel function makes it a promising tool for understanding pain-related conditions. -
Sodium Channel Blocker
BW-4030W92 is a selective sodium channel blocker that inhibits sodium ion influx. This compound is utilized in research to study the role of sodium channels in neuronal excitability and can induce ataxia, providing insights into neurological disorders. Its application is significant in pharmacological studies aiming to investigate the mechanisms of action of sodium channel modulation. -
NaV Modulator
Clathrodin is a marine alkaloid derived from Agelas sponges that functions as a modulator of voltage-gated sodium (NaV) channels. As a sodium channel neurotoxin, Clathrodin impacts sodium channel ionic conductance, making it a valuable tool for studying excitability in neurons and muscle cells. This reagent is useful in research applications involving neuropathic pain, neurotoxicity assessments, and the physiological characterization of sodium channel function. -
Sodium Channel Blocker
Olisutrigine bromide is a potent sodium channel blocker that exhibits significant analgesic properties. This compound is primarily utilized in research focused on pain modulation and the investigation of sodium channel dynamics in neurological disorders. Its efficacy in inhibiting sodium influx makes it a valuable tool for exploring therapeutic interventions in pain management.
